Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site. # Aranscia ## Sitemaps - [XML Sitemap](https://aranscia.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [InterVenn Biosciences and Aranscia Expand Commercialization Partnership for GlycoKnow™ Ovarian Cancer Diagnostic Test](https://aranscia.com/intervenn-biosciences-and-aranscia-expand-commercialization-partnership-for-glycoknow-ovarian-cancer-diagnostic-test/) - Aranscia's Technology Platform to Accelerate InterVenn's Research and Commercialization Initiatives SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 30, 2026 /PRNewswire/ -- InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced an expansion - [Reframing Pharmacogenomics in Modern Oncology: From Reactive Testing to Longitudinal Care](https://aranscia.com/reframing-pharmacogenomics-in-modern-oncology-from-reactive-testing-to-longitudinal-care/) - Reframing Pharmacogenomics in Modern Oncology: From Reactive Testing to Longitudinal Care - [DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects](https://aranscia.com/dpyd-safety-update-reducing-the-risk-of-critical-or-fatal-chemotherapy-side-effects/) - DPYD testing through AccessDx Laboratory can assist oncologists and pharmacists with identifying patients who harbor DPYD variants. - [Pharmacogenomics in Oncology: Unlocking Value, Safety, and ROI for Healthcare Systems](https://aranscia.com/pharmacogenomics-in-oncology-unlocking-value-safety-and-roi-for-healthcare-systems/) - Comprehensive PGx testing in oncology care provides a proven mechanism to reduce severe toxicity, preserve treatment efficacy, and control costs. - [AccessDx Laboratory’s Dr. Houda Hachad Named to PharmaVoice 100](https://aranscia.com/accessdx-laboratorys-dr-houda-hachad-named-to-pharmavoice-100/) - AccessDx Laboratory announces Vice President of Clinical Operations Houda Hachad, PharmD, M. Res., has been named to the 2022 PharmaVoice 100. - [Personalized prescribing in long-term care: Why it matters more than ever](https://aranscia.com/personalized-prescribing-in-long-term-care-why-it-matters-more-than-ever/) - Learn about hidden drug dangers, the application of pharmacogenomics as a tool in the LTC toolkit, and implementation and guidance for facilities. - [Neurogen Biomarking Announces Partnership with Aranscia](https://aranscia.com/neurogen-biomarking-announces-partnership-with-aranscia/) - Neurogen Biomarking, Aranscia, and AccessDx Laboratory partner for testing that measures p-tau, a specific marker for Alzheimer's disease pathology. - [Aranscia Acquires Spesana](https://aranscia.com/aranscia-acquires-spesana/) - Aranscia has acquired Spesana and its best-in-class suite of patient navigation, clinical collaboration, and oncology clinical decision support utilities. - [Arancisa's Houda Hachad Guest MedCity Influencer in MedCity News](https://aranscia.com/arancisas-houda-hachad-guest-medcity-influencer-in-medcity-news/) - In MedCity News, Houda Hachad, PharmD, M.Res, discusses PGx testing for DPYD prior to common chemotherapy treatments to avoid toxicities due to genetic variants. - [Aranscia's Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding PGx Testing in Oncology](https://aranscia.com/aranscias-houda-hachad-interviewed-in-the-journal-of-clinical-pathways-regarding-pgx-testing-in-oncology/) - Houda Hachad, PharmD, M.Res, highlights best practices for implementing PGx testing in oncology and what barriers institutions face in expanding this testing. - [Aranscia Acquires YouScript from Invitae](https://aranscia.com/aranscia-acquires-youscript-from-invitae/) - Aranscia and Invitae Corporation today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform. - [Aranscia's Dr. Joel Diamond Interviewed in HIMSS TV Digital Checkup](https://aranscia.com/aranscias-dr-joel-diamond-interviewed-in-himss-tv-digital-checkup/) - Aranscia's Dr. Joel Diamond spoke with HIMSS TV to discuss the progression of precision medicine and how molecular diagnostics works to improve patient outcomes - [Aranscia and Signature RX Announce Personalized Medication Management Program for GLP-1s](https://aranscia.com/aranscia-and-signature-rx-announce-personalized-medication-management-program-for-glp-1s/) - Aranscia and Signature RX announced a partnership to develop novel biomarkers and a personalized medication management solution for GLP-1 medications. - [Aranscia's Joel Diamond a Featured Expert in First Report Managed Care](https://aranscia.com/aranscias-joel-diamond-a-featured-expert-in-first-report-managed-care/) - Joel Diamond, MD, gives his insights on how the healthcare space changed in 2024, and what predictions he has for managed care in 2025. - [Aranscia's Houda Hachad a Featured Guest in DOTmed](https://aranscia.com/aranscias-houda-hachad-a-featured-guest-in-dotmed/) - Houda Hachad, PharmD, M.Res, shares her predictions for the state of healthcare in 2025, alongside 6 other healthcare executives, for DOTmed. - [Aranscia's Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding DPYD Testing](https://aranscia.com/aranscias-houda-hachad-interviewed-in-the-journal-of-clinical-pathways-regarding-dpyd-testing/) - Houda Hachad, PharmD, M.Res, was interviewed by the Journal of Clinical Pathways to discuss recommendations for standardizing DPYD pharmacogenomic testing. - [Aranscia's Joe Spinelli Interviewed in Electronic Health Reporter](https://aranscia.com/aranscias-joe-spinelli-interviewed-in-electronic-health-reporter/) - Joe Spinelli was featured in Electronic Health Reporter to discuss his predictions for the future of precision medicine in 2025. - [Aranscia's Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding Recent FDA Safety Announcement](https://aranscia.com/aranscias-houda-hachad-interviewed-in-the-journal-of-clinical-pathways-regarding-recent-fda-safety-announcement/) - Houda Hachad, PharmD, M.Res, was interviewed by the Journal of Clinical Pathways to discuss the FDA's recent safety announcement regarding DPD deficiency testing. - [Virtual Healthcare in 2026: Will Congress Do Something?](https://aranscia.com/virtual-healthcare-in-2026-will-congress-do-something/) - Dr. Joel Diamond, CMO of Aranscia, is featured as a guest expert to discuss expectations and predictions for virtual healthcare in 2026. - [Clinical Implications of the FDA's Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice](https://aranscia.com/clinical-implications-of-the-fdas-capecitabine-boxed-warning-integrating-dpyd-testing-into-oncology-practice/) - Houda Hachad, PharmD, M.Res, discusses the implications behind the FDA's Capecitabine boxed warning and how it affects oncology. - [The Business and Finance of Healthcare in 2026](https://aranscia.com/the-business-and-finance-of-healthcare-in-2026/) - Houda Hachad, PharmD, M.Res, joins other industry experts to discuss what they think will come for the business of healthcare in 2026. - [There Seems to be No Limits on AI in Clinical Settings for 2026](https://aranscia.com/there-seems-to-be-no-limits-on-ai-in-clinical-settings-for-2026/) - Houda Hachad, PharmD, M.Res, joins other industry experts to discuss how they think AI - artificial intelligence - will shape healthcare in 2026 - [Hospitals in 2026: Predictions for patient care, technology, and more](https://aranscia.com/hospitals-in-2026-predictions-for-patient-care-technology-and-more/) - Joel Diamond, MD, is featured as a guest industry expert to discuss what we can predict for the rapidly changing landscape for hospitals in 2026. - [Healthcare at Home – 2026 Health IT Predictions](https://aranscia.com/healthcare-at-home-2026-health-it-predictions/) - Houda Hachad, PharmD, M.Res, is featured as a guest expert in a discussion about what we can see coming in 2026 for healthcare at home. - [InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test](https://aranscia.com/intervenn-biosciences-partners-with-aranscia-to-accelerate-commercialization-of-glycoknow-non-invasive-ovarian-cancer-diagnostic-test/) - InterVenn Biosciences and Aranscia announced a partnership to expand the availability of InterVenn’s flagship GlycoKnowTM Ovarian cancer diagnostic test. - [Healthcare Interoperability – 2026 Health IT Predictions](https://aranscia.com/healthcare-interoperability-2026-health-it-predictions/) - Joel Diamond, MD, is featured as a guest industry expert to discuss healthcare interoperability predictions for 2026. - [The End of the Guessing Game: Why Primary Care is Finally Ready for Pharmacogenomics](https://aranscia.com/the-end-of-the-guessing-game-why-primary-care-is-finally-ready-for-pharmacogenomics/) - Joel Diamond, MD, dispels myths surrounding pharmacogenomics in primary care in this newest article by HIT Consultant Media. - [PGx Testing: Specialists Benefit From, and Build Upon Oncology’s Success](https://aranscia.com/pgx-testing-specialists-benefit-from-and-build-upon-oncologys-success/) - Carla Balch goes further in-depth on how oncology has adopted PGx testing and the benefits they've seen in this article in MedCity News. - [PGx Can Help LTC Keep Up with Medication Oversight Evolution](https://aranscia.com/pgx-can-help-ltc-keep-up-with-medication-oversight-evolution/) - Houda Hachad, PharmD, M.Res, explains how PGx testing supports LTC with the medication oversight evolution in this article in McKnight's Long-Term Care News. ## Pages - [Home](https://aranscia.com/) - We focus on building high-quality diagnostic systems built to help clinicians improve care outcomes. Our portfolio includes 2bPrecise, AccessDx, Spesana, and YouScript. - [Legal](https://aranscia.com/legal/) - Table of Contents Privacy policy Cookie policy Terms and conditions EULA ## Categories - [News](https://aranscia.com/category/news/) - [Press Release](https://aranscia.com/category/press-release/) ## Tags - [AI](https://aranscia.com/tag/ai/) - [Artificial Intelligence](https://aranscia.com/tag/artificial-intelligence/) - [Hospitals](https://aranscia.com/tag/hospitals/) - [Telehealth](https://aranscia.com/tag/telehealth/) - [Interoperability](https://aranscia.com/tag/interoperability/) - [Healthcare](https://aranscia.com/tag/healthcare/) - [Primary Care](https://aranscia.com/tag/primary-care/) - [Pharmacogenomics](https://aranscia.com/tag/pharmacogenomics/) - [PGx](https://aranscia.com/tag/pgx/) - [Oncology](https://aranscia.com/tag/oncology/) - [Carla Balch](https://aranscia.com/tag/carla-balch/) - [LTC](https://aranscia.com/tag/ltc/) - [PALTC](https://aranscia.com/tag/paltc/) - [LTPAC](https://aranscia.com/tag/ltpac/) - [liquid biopsy](https://aranscia.com/tag/liquid-biopsy/) - [ovarian cancer](https://aranscia.com/tag/ovarian-cancer/) - [Pharmacogenetics](https://aranscia.com/tag/pharmacogenetics/) - [AccessDx](https://aranscia.com/tag/accessdx/) - [glycoproteomics](https://aranscia.com/tag/glycoproteomics/) - [YouScript](https://aranscia.com/tag/youscript/) - [Precision Medicine](https://aranscia.com/tag/precision-medicine/) - [healthcare at-home](https://aranscia.com/tag/healthcare-at-home/) - [IT Predictions](https://aranscia.com/tag/it-predictions/) - [patient care](https://aranscia.com/tag/patient-care/) - [technology](https://aranscia.com/tag/technology/) - [healthcare technology](https://aranscia.com/tag/healthcare-technology/) - [health tech](https://aranscia.com/tag/health-tech/) - [HealthIT Answers](https://aranscia.com/tag/healthit-answers/) - [Healthcare IT](https://aranscia.com/tag/healthcare-it/) - [Health AI](https://aranscia.com/tag/health-ai/) - [Healthcare AI](https://aranscia.com/tag/healthcare-ai/) - [Personalized Medicine](https://aranscia.com/tag/personalized-medicine/) - [GLP-1](https://aranscia.com/tag/glp-1/) - [Biomarkers](https://aranscia.com/tag/biomarkers/) - [healthcare finanance](https://aranscia.com/tag/healthcare-finanance/) - [healthcare business](https://aranscia.com/tag/healthcare-business/) - [health finance](https://aranscia.com/tag/health-finance/) - [health business](https://aranscia.com/tag/health-business/) - [Capecitabine](https://aranscia.com/tag/capecitabine/) - [DPYD](https://aranscia.com/tag/dpyd/) - [DPYD Testing](https://aranscia.com/tag/dpyd-testing/) - [5-FU](https://aranscia.com/tag/5-fu/) - [FDA](https://aranscia.com/tag/fda/) - [colon cancer](https://aranscia.com/tag/colon-cancer/) - [rectal cancer](https://aranscia.com/tag/rectal-cancer/) - [adenocarcinoma](https://aranscia.com/tag/adenocarcinoma/) - [FDA boxed warning](https://aranscia.com/tag/fda-boxed-warning/) - [Managed Care](https://aranscia.com/tag/managed-care/) - [DPD](https://aranscia.com/tag/dpd/) - [Chemotherapy](https://aranscia.com/tag/chemotherapy/) - [virtual healthcare](https://aranscia.com/tag/virtual-healthcare/) - [congress](https://aranscia.com/tag/congress/) - [Health predictions](https://aranscia.com/tag/health-predictions/) - [healthcare systems](https://aranscia.com/tag/healthcare-systems/) - [cancer](https://aranscia.com/tag/cancer/) - [oncology costs](https://aranscia.com/tag/oncology-costs/) - [oncologists](https://aranscia.com/tag/oncologists/) - [chemo](https://aranscia.com/tag/chemo/) - [xeloda](https://aranscia.com/tag/xeloda/) - [DPD Deficiency](https://aranscia.com/tag/dpd-deficiency/) - [Spesana](https://aranscia.com/tag/spesana/) - [polypharmacy](https://aranscia.com/tag/polypharmacy/) - [McKnights](https://aranscia.com/tag/mcknights/) - [p-tau](https://aranscia.com/tag/p-tau/) - [phosphorylated tau](https://aranscia.com/tag/phosphorylated-tau/) - [2bPrecise](https://aranscia.com/tag/2bprecise/) - [AccessDx Laboratory](https://aranscia.com/tag/accessdx-laboratory/) - [Alzheimer's disease](https://aranscia.com/tag/alzheimers-disease/) - [phosphorylated tau 217](https://aranscia.com/tag/phosphorylated-tau-217/) - [CancerCare](https://aranscia.com/tag/cancercare/) - [PersonalizedMedicine](https://aranscia.com/tag/personalizedmedicine/) - [PrecisionMedicine](https://aranscia.com/tag/precisionmedicine/) - [InterVenn Biosciences](https://aranscia.com/tag/intervenn-biosciences/) - [Press Release](https://aranscia.com/tag/press-release/)